Adizie, JB;
Tweedie, J;
Khakwani, A;
Peach, E;
Hubbard, R;
Wood, N;
Gosney, JR;
... Navani, N; + view all
(2021)
Biomarker Testing for People With Advanced Lung Cancer in England.
JTO Clinical and Research Reports
, 2
(6)
, Article 100176. 10.1016/j.jtocrr.2021.100176.
Preview |
Text
1-s2.0-S2666364321000357-main.pdf - Published Version Download (565kB) | Preview |
Abstract
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. // Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. // Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. // Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
| Type: | Article |
|---|---|
| Title: | Biomarker Testing for People With Advanced Lung Cancer in England |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jtocrr.2021.100176 |
| Publisher version: | https://doi.org/10.1016/j.jtocrr.2021.100176 |
| Language: | English |
| Additional information: | © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Biomarkers, Mutation testing, Non–small cell lung cancer, Personalized medicine, Targeted therapy |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10142356 |
Archive Staff Only
 |
View Item |
